USPTO serial 79376665
SPHERE FLUIDICS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 26, 2025
- Examiner
- ALLEN, BIANCA LEIGH
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with SPHERE FLUIDICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
MICHELLE E. TOCHTROP
MICHELLE E. TOCHTROP Chrisman Gallo Tochtrop LLC6509 Brecksville Road #31550Independence, OH 44131-4854United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for use in industry and science; chemical reagents, other than for medical or veterinary purposes; chemical solutions, namely, gas soluble oils containing a surfactant, azo-dye, and biological reagents; surfactants for use in drug discovery and development, medical diagnostic applications, genetic research, synthetic biology and life sciences research namely, fluorinated or non-fluorinated surfactants, biocompatible surfactants, emulsifiers, dispersants, wetting agents; chemical coating agents for use in improving or enabling microfluidic processes namely, surfactants, polymers and other coating agents for enhancing fluid flow and controlling surface wettability in microfluidic devices and systems; chemical agents for de-emulsifying solutions, namely, demulsifiers, destabilizers, and phase-separating compounds, proteins and enzymes for breaking down emlusions; unprocessed polymers; pico droplets and microfluids for use in cell detection and molecular discovery being microscale fluid compartments encapsulated in an immiscible carrier fluid or microscale fluid compartments surrounding by an immiscible fluid shell in an immiscible carrier fluid for use in cell detection and molecular discovery, other than for medical or veterinary purposes | ACTIVE | — |
| 005 | Chemical preparations for medical purposes, namely, preparations for the treatment of cancer, cardiovascular, immunological, central nervous system, and metabolic diseases, genetic diseases, microbial infections, viral infections | ACTIVE | — |
| 009 | Laboratory apparatus and instruments, namely, pico droplet production instruments in the nature of microfluidic and emulsification instruments; Laboratory apparatus and instruments, namely, single cell analysis and isolation systems comprised of flow cells, droplet generators, segmented flow chips, single-cell encapsulation modules, and integrated microfluidic components; Laboratory apparatus and instruments, namely, cell engineering systems comprised of flow cells, droplet generators, segmented flow chips, single-cell encapsulation modules, and integrated microfluidic components; laboratory apparatus and instruments for use in cell detection and molecular discovery, namely, pico droplet production instruments in the nature of microfluidic and emulsification instruments; laboratory apparatus and instruments for use in cell detection and molecular discovery, namely, single cell analysis and isolation systems comprised of flow cells, droplet generators, segmented flow chips, single-cell encapsulation modules, and integrated microfluidic components; laboratory apparatus and instruments for use in cell detection and molecular discovery, namely, cell engineering systems comprised of flow cells, droplet generators, segmented flow chips, single-cell encapsulation modules, and integrated microfluidic components; laboratory apparatus and instruments for the analysis, retrieval and discovery of single cells, genes, or populations of proteins and molecules, contained in individual pico droplets, namely, pico droplet production instruments in the nature of microfluidic and emulsification instruments; laboratory apparatus and instruments for the analysis, retrieval and discovery of single cells, genes, or populations of proteins and molecules, contained in individual pico droplets, namely, single cell analysis and isolation systems comprised of flow cells, droplet generators, segmented flow chips, single-cell encapsulation modules, and integrated microfluidic components; laboratory apparatus and instruments for the analysis, retrieval and discovery of single cells, genes, or populations of proteins and molecules, contained in individual pico droplets, namely, cell engineering systems comprised of flow cells, droplet generators, segmented flow chips, single-cell encapsulation modules, and integrated microfluidic components; laboratory apparatus and instruments for the analysis of biomarkers, namely, pico droplet production instruments in the nature of microfluidic and emulsification instruments; laboratory apparatus and instruments for the analysis of biomarkers, namely, single cell analysis and isolation systems comprised of flow cells, droplet generators, segmented flow chips, single-cell encapsulation modules, and integrated microfluidic components; laboratory apparatus and instruments for the analysis of biomarkers, namely, cell engineering systems comprised of flow cells, droplet generators, segmented flow chips, single-cell encapsulation modules, and integrated microfluidic components; replacement parts and fittings in the nature of reflective mirrors for scientific use, tubing for scientific use, fluidic components namely, flow cells, controlled volume pumps and control valves for regulating the flow of gases and liquids, optical components namely, lasers for non-medical purposes, and light detectors, and electronic components namely, circuit boards, power supplies and electronic data processing apparatus for all the aforesaid goods | ACTIVE | — |
| 042 | Scientific research and development; biopharmaceutical discovery being drug discovery and biopharmaceutical drug development; cell therapy engineering; scientific research and development, namely, bioproduction and synthetic biology, analysis and isolation | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Sphere Fluidics Limited
- Other trademarks owned by Sphere Fluidics Limited
- Other trademarks owned by Sphere Fluidics Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Similar marks named SPHERE FLUIDICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 26, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 6, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 6, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 26, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 26, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 26, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 10, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 10, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 4, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 6, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 6, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 6, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 6, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 6, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 21, 2025 | GNS1 | NOTIFICATION OF SUBSEQUENT FINAL EMAILED | — |
| Apr 21, 2025 | GNCF | CONTINUATION OF FINAL REFUSAL E-MAILED | — |
| Apr 21, 2025 | CNCF | ACTION CONTINUING A FINAL - COMPLETED | — |
| Mar 29, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Mar 18, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 18, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 18, 2025 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Mar 11, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 11, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jan 28, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 28, 2025 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jan 28, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 28, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 28, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jan 28, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Sep 30, 2024 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Sep 30, 2024 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 30, 2024 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 4, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 4, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 4, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 27, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 4, 2024 | ATRV | ATTORNEY REVIEW COMPLETED | — |
| Mar 4, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 4, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 27, 2024 | CREV | CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED | — |
| Feb 10, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 9, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 6, 2024 | RFWR | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW | — |
| Jan 20, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 19, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 17, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 15, 2023 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Aug 22, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 18, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 17, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |